# Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC

> **NCT07639242** · PHASE2 · SUSPENDED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Lung Cancer
- Lung Cancer (NSCLC)
- Locally Advanced NSCLC
- Metastatic NSCLC - Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Olomorasib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07639242
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-10
- **Primary completion:** 2030-06-21
- **Final completion:** 2030-06-21
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** Administrative
- **Last updated:** 2026-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07639242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07639242, "Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07639242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*